Drugs / CK0803
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05695521 | Apr 2023 → May 2026 overdue | amyotrophic lateral sclerosis | Cellenkos, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CK0803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05695521 ↗ |
| Modality | Cell therapy | “allogeneic, cord blood derived T regulatory cells” NCT05695521 ↗ |
| Route | Intravenous | “administered intravenously” NCT05695521 ↗ |